Recent findings leading to the reported association of fenfluramine and phentermine use with valvular abnormalities and pulmonary hypertension are discussed. The authors provide current American Heart Association and United States Department of Health and Human Services guidelines for the evaluation and treatment of patients exposed to these agents.
|Original language||English (US)|
|Number of pages||3|
|State||Published - Dec 1 1998|
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine